These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 8047080

  • 1. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major.
    Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, Allen CJ, Farrell DE, Harris JW.
    N Engl J Med; 1994 Sep 01; 331(9):567-73. PubMed ID: 8047080
    [Abstract] [Full Text] [Related]

  • 2. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P.
    Blood Cells Mol Dis; 2009 Sep 01; 42(3):247-51. PubMed ID: 19233692
    [Abstract] [Full Text] [Related]

  • 3. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
    Delea TE, Hagiwara M, Thomas SK, Baladi JF, Phatak PD, Coates TD.
    Am J Hematol; 2008 Apr 01; 83(4):263-70. PubMed ID: 17924547
    [Abstract] [Full Text] [Related]

  • 4. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
    Sheth S, Tang H, Jensen JH, Altmann K, Prakash A, Printz BF, Hordof AJ, Tosti CL, Azabagic A, Swaminathan S, Brown TR, Olivieri NF, Brittenham GM.
    Ann N Y Acad Sci; 2005 Apr 01; 1054():358-72. PubMed ID: 16339684
    [Abstract] [Full Text] [Related]

  • 5. Survival in medically treated patients with homozygous beta-thalassemia.
    Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR.
    N Engl J Med; 1994 Sep 01; 331(9):574-8. PubMed ID: 8047081
    [Abstract] [Full Text] [Related]

  • 6. A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.
    Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung EB, Calvelli L, Quirolo K, Foote D, Harmatz P, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Sep 01; 1054():486-91. PubMed ID: 16339703
    [Abstract] [Full Text] [Related]

  • 7. [Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major].
    Rodríguez Galindo C, Ortega Aramburu JJ, Alonso JL, Albisu M, Casaldáliga J, Díaz de Heredia C, Olivé T, Bastida P.
    Med Clin (Barc); 1994 May 21; 102(19):721-4. PubMed ID: 8041200
    [Abstract] [Full Text] [Related]

  • 8. Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
    Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A, Larbaa D, Dreyfus F, Beyne-Rauzy O, Chaury MP, Roy L, Cheze S, Morel P, Fenaux P, GFM (Groupe Francophone des Myélodysplasies).
    Leuk Res; 2010 Jul 21; 34(7):864-70. PubMed ID: 20129667
    [Abstract] [Full Text] [Related]

  • 9. Effect of age at the start of iron chelation therapy on gonadal function in beta-thalassemia major.
    Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ.
    N Engl J Med; 1990 Sep 13; 323(11):713-9. PubMed ID: 2388669
    [Abstract] [Full Text] [Related]

  • 10. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
    Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R.
    Arch Intern Med; 1985 Jul 13; 145(7):1217-21. PubMed ID: 3925909
    [Abstract] [Full Text] [Related]

  • 11. Intravenous chelation therapy during transplantation for thalassemia.
    Gaziev D, Giardini C, Angelucci E, Polchi P, Galimberti M, Baronciani D, Erer B, Maiello A, Lucarelli G.
    Haematologica; 1995 Jul 13; 80(4):300-4. PubMed ID: 7590497
    [Abstract] [Full Text] [Related]

  • 12. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
    Grosse R, Lund U, Caruso V, Fischer R, Janka GE, Magnano C, Engelhardt R, Dürken M, Nielsen P.
    Ann N Y Acad Sci; 2005 Jul 13; 1054():429-32. PubMed ID: 16339692
    [Abstract] [Full Text] [Related]

  • 13. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
    Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A.
    Haematologica; 2004 Oct 13; 89(10):1187-93. PubMed ID: 15477202
    [Abstract] [Full Text] [Related]

  • 14. [Arrhythmia in thalassemia major: evaluation of iron chelating therapy by dynamic ECG].
    Cavallaro L, Meo A, Busà G, Coglitore A, Sergi G, Satullo G, Donato A, Calabrò MP, Miceli M.
    Minerva Cardioangiol; 1993 Oct 13; 41(7-8):297-301. PubMed ID: 8233011
    [Abstract] [Full Text] [Related]

  • 15. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function.
    Marciani MG, Cianciulli P, Stefani N, Stefanini F, Peroni L, Sabbadini M, Maschio M, Trua G, Papa G.
    Haematologica; 1991 Oct 13; 76(2):131-4. PubMed ID: 1937171
    [Abstract] [Full Text] [Related]

  • 16. Insulin resistance and beta cell function in chronically transfused patients of thalassemia major.
    Suvarna J, Ingle H, Deshmukh CT.
    Indian Pediatr; 2006 May 13; 43(5):393-400. PubMed ID: 16735760
    [Abstract] [Full Text] [Related]

  • 17. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct 13; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 18. Increased risk of diabetes mellitus in beta- thalassemia major due to iron overload.
    Zuppinger K, Molinari B, Hirt A, Imbach P, Gugler E, Tönz O, Zurbrügg RP.
    Helv Paediatr Acta; 1979 Oct 13; 34(3):197-207. PubMed ID: 500381
    [Abstract] [Full Text] [Related]

  • 19. Hepatic iron concentration and total body iron stores in thalassemia major.
    Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G.
    N Engl J Med; 2000 Aug 03; 343(5):327-31. PubMed ID: 10922422
    [Abstract] [Full Text] [Related]

  • 20. Glutathione S-transferase M1 gene polymorphisms are associated with cardiac iron deposition in patients with beta-thalassemia major.
    Wu KH, Chang JG, Ho YJ, Wu SF, Peng CT.
    Hemoglobin; 2006 Aug 03; 30(2):251-6. PubMed ID: 16798650
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.